Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study

Background: Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes of rituximab plus chemothera...

Full description

Bibliographic Details
Main Authors: Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, Ming-Zhi Zhang, Wei Li, Yu Hu, Xiao-Hong Zhang, Yu-Huan Gao, Zuo-Xing Niu, Ru Feng, Wei Wang, Jie-Wen Peng, Xiao-Lin Li, Xue-Nong Ouyang, Chang-Ping Wu, Wei-Jing Zhang, Yun Zeng, Zhen Xiao, Ying-Min Liang, Yong-Zhi Zhuang, Ji-Shi Wang, Zi-Min Sun, Hai Bai, Tong-Jian Cui, Ji-Feng Feng
Format: Article
Language:English
Published: Wolters Kluwer 2018-01-01
Series:Chinese Medical Journal
Subjects:
Asian; Hematopoietic Malignancy; Hepatitis B Virus; Observational Study; Rituximab
Online Access:http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=15;spage=1767;epage=1775;aulast=Wu

Internet

http://www.cmj.org/article.asp?issn=0366-6999;year=2018;volume=131;issue=15;spage=1767;epage=1775;aulast=Wu

Similar Items